Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)

NCT00444925 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00444925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00444925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2007
Completion date
July 31, 2008
Enrollment
1,712 (actual)
Sites
178

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder